During a median follow-up of 1.81 years in the AMPLITUDE-O trial, which enrolled patients with T2D and a history of CV disease or CKD, efpeglenatide reduced the risk of HHF by 39% [38], independent of concurrent SGLT2 inhibitor use (15.2% of participants) [39]. The gene discussed is SLC5A2; the disease is chronic kidney disease.